Plain language summary of the himalaya study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

dc.contributor.author	Abou-Alfa, Ghassan K.
dc.contributor.author	Lau, George
dc.contributor.author	Kudo, Masatoshi
dc.contributor.author	Varela Calvo, María
dc.date.accessioned	2024-04-18T07:21:13Z
dc.date.available	2024-04-18T07:21:13Z
dc.date.issued	2023
dc.identifier.citation	Future Oncology, 19(38), (2023); doi:10.2217/fon-2023-0486
dc.identifier.issn	1479-6694
dc.identifier.issn	1744-8301
dc.identifier.uri	https://hdl.handle.net/10651/72239
dc.description.sponsorship	AstraZeneca; Good Publication Practice (GPP 2022) guidelines
dc.language.iso	eng
dc.relation.ispartof	Future Oncology
dc.rights	©,
dc.source	WOS:001062933700001
dc.title	Plain language summary of the himalaya study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)
dc.type	journal article
dc.identifier.doi	10.2217/fon-2023-0486
dc.relation.publisherversion	http://dx.doi.org/10.2217/fon-2023-0486

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.